Andere Sprachen MoonLake Immunotherapeutics

Aktien

A3DFA7

KY61559X1045

MLTX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 05.06.2024			% 5 Tage	% 1. Jan.
42,91 ^USD	+5,15 %		+4,45 %	-28,95 %

07.05.	MoonLake Immunotherapeutics Q1 Nettoverlust weitet sich aus	MT
07.05.	MoonLake Immunotherapeutics meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa	16.05.
MoonLake Immunotherapeutics Q1 Net Loss Widens	07.05.
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update	07.05.
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	10.04.
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions	10.04.
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions	10.04.
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	11.03.
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10.03.
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	10.03.
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day	10.03.
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024	04.03.
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	04.03.
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	01.03.
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	01.03.
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	29.02.
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29.02.
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10	29.02.
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab in Hidradenitis Suppurativa	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen MoonLake Immunotherapeutics

Aktien

A3DFA7

KY61559X1045

MLTX

Andere Sprachen

Filter